Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTK6 shRNA
- Development stage
- Unknown
- Lead developer
- GenePharma
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral, Intraperitoneal
01
Overview
PTK6 shRNA (short hairpin RNA targeting Protein Tyrosine Kinase 6) is a research-use-only genetic tool designed to knock down the expression of PTK6 (also known as Breast Tumor Kinase, or BRK). PTK6 is a non-receptor tyrosine kinase that is overexpressed in various cancers, including breast, prostate, ovarian, and pancreatic cancers, where it acts as an oncogenic driver promoting cell survival, proliferation, migration, and epithelial-mesenchymal transition (EMT). By targeting PTK6 mRNA for degradation via the RNA interference (RNAi) pathway, PTK6 shRNA downregulates PTK6 protein levels. This knockdown has been shown in preclinical research to induce apoptosis (often mediated by the upregulation of the pro-apoptotic protein Bim) and inhibit the growth and metastasis of cancer cells, including those resistant to standard therapies. It is widely used in laboratory settings to study the kinase-dependent and kinase-independent functions of PTK6.
- Other names
- PTK6 short hairpin RNAPTK-6 short hairpin RNAPTK 6 short hairpin RNAshPTK6shPTK-6shPTK 6shRNA targeting PTK6
02
Targets
PTK6 (Protein-tyrosine kinase 6)BIM
Beyond the preview
Go deeper on PTK6 shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTK6 shRNA.